Word

BIOTHEUS

Status

Registered

Status Code

700

Status Date

Tuesday, November 7, 2023

Serial Number

79344182

Registration Number

7209518

Registration Date

Tuesday, November 7, 2023

Mark Type

3000

Filing Date

Thursday, April 14, 2022

Published for Opposition

Tuesday, August 22, 2023

Trademark Owner History

Biotheus Inc. - Original Registrant

Classifications

5 Medicines used for treating cancers; biological preparations used for treating cancer; anti-cancer pharmaceutical preparations; medicines for human purposes for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; pharmaceutical preparations for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; chemico-pharmaceutical preparations for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; medicines for medical purposes for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; chemical preparations for pharmaceutical purposes for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; biological preparations for medical purposes for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; biochemicial medicines for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases; medicines in the form of injections for the treatment of cancer, immune function affection, nervous system diseases, respiratory system diseases, hematological system diseases, circulatory system diseases, hypertensive diseases, diabetic diseases, digestive system diseases, bone and joint diseases, endocrine and metabolic system diseases, ankylosing spondylitis disease, psoriasis, lupus erythematosus disease, rheumatoid arthritis diseases, immunomodulatory diseases, urinary system diseases, skin system diseases, reproductive system diseases

42 Scientific research in the field of medication evaluation; quality control evaluation for others; scientific research in the nature of conducting clinical trials for others; scientific research in the field of antibody; services of medical laboratory

The mark consists of the wording "BIOTHEUS" in stylized font above seven Chinese characters positioned horizontally; to the right of the literal element is the stylized depiction of six curving lines of varying sizes surrounding a single shaded dot.
The transliteration of the non-Latin characters in the mark is "PU MI SI SHENG WU JI SHU" wherein the word "PU" means "GENERAL," the word "MI" means "METER," the word "SI" means "THIS," and the wording "SHENG WU JI SHU" means "BIOTECHNOLOGY" in English, and the combination of Chinese characters as a whole has no meaning.
THE CHINESE CHARACTERS WHICH TRANSLITERATE TO "SHENG WU JI SHU"

Trademark Events

Mar 4, 2024

Final Decision Transaction Processed By Ib

Feb 8, 2024

Final Disposition Notice Sent To Ib

Feb 8, 2024

Final Disposition Processed

Feb 7, 2024

Final Disposition Notice Created, To Be Sent To Ib

Nov 7, 2023

Notice Of Registration Confirmation Emailed

Nov 7, 2023

Registered-Principal Register

Aug 22, 2023

Official Gazette Publication Confirmation E-Mailed

Aug 22, 2023

Published For Opposition

Aug 21, 2023

Notification Processed By Ib

Aug 2, 2023

Notification Of Possible Opposition Sent To Ib

Aug 2, 2023

Notice Of Start Of Opposition Period Created, To Be Sent To Ib

Aug 2, 2023

Notification Of Notice Of Publication E-Mailed

Jul 14, 2023

Approved For Pub - Principal Register

Jul 13, 2023

Teas/Email Correspondence Entered

Jul 13, 2023

Correspondence Received In Law Office

Jul 13, 2023

Teas Response To Office Action Received

Apr 19, 2023

Refusal Processed By Ib

Mar 30, 2023

Non-Final Action Mailed - Refusal Sent To Ib

Mar 30, 2023

Refusal Processed By Mpu

Feb 8, 2023

Non-Final Action (Ib Refusal) Prepared For Review

Feb 7, 2023

Non-Final Action Written

Feb 1, 2023

Assigned To Examiner

Sep 10, 2022

New Representative At Ib Received

Jul 12, 2022

Application Filing Receipt Mailed

Jul 8, 2022

New Application Office Supplied Data Entered

Jul 7, 2022

Sn Assigned For Sect 66a Appl From Ib